Antisense oligonucleotide therapy - Chinook Therapeutics/Ionis Pharmaceuticals
Alternative Names: ASO therapy - Chinook Therapeutics/Ionis PharmaceuticalsLatest Information Update: 18 Aug 2023
At a glance
- Originator Chinook Therapeutics; Ionis Pharmaceuticals
- Class Antisense oligonucleotides; Urologics
- Mechanism of Action Protein synthesis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Renal failure
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 16 May 2023 Chinook Therapeutics collaborates with Ionis Pharmaceuticals for the discovery, development and commercialisation of antisense oligonucleotide therapy for chronic kidney disease
- 16 May 2023 Preclinical trials in Renal failure in USA (Parenteral)